Quintain Consulting Presentation

Click here to load reader

  • date post

  • Category


  • view

  • download


Embed Size (px)


Company presentation, including background, services and expertise

Transcript of Quintain Consulting Presentation

  • 1. making the leap from bionano research to commercialisation www.quintainconsulting.com.au
  • 2. Quintain Consulting - Overview Quintain Consulting Pty Ltd is a private firm, which offers services in the area of bionanotechnology commercialisation Founded in July 2009 by Dr Bob Irving and Dr Jeanette Pritchard Building on knowledge developed during time at NVA and NanoVic, to offer expert guidance to government and academic groups, companies and investors who are involved in bionanotechnology developments Over 40 years combined experience in biotechnology and bionanotechnology industries in Australia, UK & Canada
  • 3. Key Services Strategic Advice- For research, development, industrial and government bodies who are involved or looking to become involved in bionanotechnology product development and want to increase their understanding of local and worldwide markets and opportunities. Asset Management- For parties with large and small IP portfolios. Technology Assessment- For funding and investment groups / individuals who would like an expert opinion on bionanotechnology opportunities being presented. Project and Process Management- Assembly and management of multisector / multidisciplinary teams. Management of product development and commercialisation processes, including input into Australian and US regulatory issues.
  • 4. Expertise Dr Bob Irving Dr Jeanette Pritchard Founder & Director Founder & Director Bob has more than 25 years experience in diagnostic and Jeanette has 15 years experience working in device therapeutic technology development in Australia, development, over 8 of which have been within the Canada and the UK. He has led programs within CSIRO, biotechnology industry in the UK and Australia. Jeanette Diagnostics CRCs and biotech companies worldwide and has extensive experience in project management, business has been instrumental in the establishment and launch development and commercialisation of devices for rapid, of start-up companies such as Evogenix. point-of-care disease detection and on-site water monitoring. Bob advises industry bodies and government on nanotechnology strategy, development and Jeanette participates in the Victorian Government Skills and commercialization, and participated in the Australian Public Support Working Group, as part of a broad initiative Academy of Technological Sciences and Engineering to develop actions for implementation of the five year mission to France, organised in association with the Biotechnology Strategic Plan. National Academy of Technologies of France. Jeanette completed her PhD at the University of Newcastle Bob has a PhD through the Imperial Cancer Research upon Tyne (UK), with a research topic on development of a Fund (London, UK) with a research topic on prostate detection system for cardiac marker proteins. cancer.
  • 5. Current Projects InCellution Commercialisation and management of InCellution IP, assigned from AdAlta Pty Ltd. The InCellution process uses natural somatic hypermutation processes that occur in human B-cells to produce improved diagnostic and therapeutic reagents. Currently in discussions with overseas group and investors. BioDetectors Engagement by NSW-based start-up diagnostics company BioDetectors Pty Ltd, to manage its business development and commercialisation activities. Trinity Bioactives / NanoVentures Australia Management of the completion of the current phase of the meningococcal diagnostic test development work. NanoVentures Australia Feasibility study of sensing and delivery devices currently being assessed by a medical devices company.
  • 6. Case Study 1 Identification of Technologies and IP for Sensing and Delivery; Negotiation and Coordination of Licenses and Assignments Convenient systems (for both patient and healthcare providers) for monitoring health/drug status and delivery of medications require continuous monitoring, signaling and delivery devices with minimal disruption to the patient. Approach Evaluated sensing systems in development and available commercially and gained access to sensor IP developed within local university (RMIT). Proposed a sensing and delivery solution to fulfill the needs of the client company. Negotiated License and Assignment Agreements. Result: Licensing and Assignment Agreements for required technologies completed and product development plan prepared.
  • 7. Case Study 2 Licensing out Transdermal Delivery Technologies for large molecule immunotherapies Each year in the US alone, 29,000 anaphylactic reactions to foods are treated in emergency departments and nearly 200 deaths occur due to food allergies. Seafood allergies are the most common cause, with life-threatening reactions. Traditionally, anti-allergy or tolerising reagents are injected into patients, but more direct access to the immune system is preferred. Approach (through NVA): Negotiated Co-Development and Licensing Agreement with the company, for the evaluation and in vivo testing of the Formulation and Transdermal Patch delivery of its anti-allergy therapeutic(s). Result: Successful license agreement negotiation and execution. Managed development plan; coordinated the materials, formulation and testing of the reagents.
  • 8. Case Study 3 The pharmaceutical industry has a need for improved therapeutic and diagnostic antibody-based reagents to provide better health outcomes for patients As monoclonal and recombinant antibodies become increasingly accessible to the clinic for treating a range of disease states including cancer, it is becoming necessary for these reagents to be optimised for use in humans and in their effectiveness. Approach (through Diagnostics CRC): Technologies and expertise in the UK, Germany and Australia were identified and harnessed, and funding to support the team secured. IP was protected. Investment funding was secured to develop the technology into a commercially relevant process. The investment was used to establish a start-up company for this purpose. Result: The start-up company- EvoGenix- which successfully developed the commercial process went to IPO and then merged with Peptech to form Arana. Arana has now has been acquired by Cephalon (US).
  • 9. Case Study 4 Develop an understanding and raise awareness of future diagnostics appropriate to the Indonesian region Improved next generation diagnostic technologies and tests developed in Australia were of interest to researchers, clinicians and diagnostics companies in Indonesia. They needed to have the opportunity to understand and evaluate their applications and to make links with developers of the technologies and tests. State of the Art equipment was readily available but not strategies or expertise for its use. Approach (through CSIRO): Coordinated researchers from Institutions and Universities in Queensland and Victoria, along with WHO and Australian Biotechnology Diagnostics Companies, with leaders in the Inter- University Biotechnology Centres in Bandung and Yogyakarta, for a series of Indonesian workshops. Result: Two 2-day workshops with academic, applied scientists and clinicians from the Centres, Universities and diagnostics companies from across Indonesia. Institutions in Australia supported or provided access to Indonesian researchers for follow-up after the workshops.
  • 10. Contact Suite 213 1 Queens Road Melbourne VIC 3004 Australia [email protected] [email protected] www.quintainconsulting.com.au